The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial

Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammersen, J., Birndt, S., Döhner, K., Reuken, P., Stallmach, A., Sauerbrey, P., La Rosée, F., Pfirrmann, M., Fabisch, C., Weiss, M., Träger, K., Bremer, H., Russo, S., Illerhaus, G., Drömann, D., Schneider, S., La Rosée, P., Hochhaus, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457200/
https://www.ncbi.nlm.nih.gov/pubmed/37507425
http://dx.doi.org/10.1038/s41375-023-01979-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457200/
https://www.ncbi.nlm.nih.gov/pubmed/37507425
http://dx.doi.org/10.1038/s41375-023-01979-w

Ejemplares similares